Get a fresh start.
Add this topic to your myFT Digest for news straight to your inbox
ViiV Healthcare regimen hoped to offer less toxic alternative to daily tablets
Lengthy inventory of longstanding investigations prompts tough decisions
Two of the anti-fraud agency’s biggest and longest-running cases are brought to a close
UK drugmaker warns 2019 earnings likely to be hit by generic rival to Advair asthma drug
UK group to pay up to €3.7bn to co-develop novel class of immunology
Some find group’s prospects not worth waiting for, but others see recipe for success
Philip Hampton praised as ‘change agent’ despite concerns over share price
The CEO has lost no time in ruthlessly reshaping the health and pharmaceuticals group
Chief Emma Walmsley’s JV plan will make investors’ ears perk up
Cash influx intended to bolster search for blockbuster drugs and dealmaking
Drugmaker plans to split in two after spinning off consumer product unit
Deal leaves UK pharma group in the driving seat, without a cash acquisition cost
Prognosis is for further financial pain for chronic GlaxoSmithKline shareholders
The company is committed to pharma but that looks expensive
Anglo-Dutch group’s acquisition of malted beverages is a bet on India growth
Shares lose 7 per cent on news of drugmaker’s first big acquisition under Emma Walmsley
Anglo-Dutch consumer company beats out rival bid from Nestlé for $4bn nutrition business
UK drugmaker tightens full-year guidance towards upper end of expectations
Competition rises to secure GlaxoSmithKline’s prized malted drink brand
Prevention trial aims to prove to cash strapped service that products are value for money
A niche drink in India would not come cheap for bidders
Monthly injections to replace daily treatment as health group seeks to boost market share
